Clinical Trials

31 enrolled

Carcinoma, Renal Cell

NCT03017820 2026-04-13

A Vaccine (VSV-hIFNβ-NIS) With or Without Cyclophosphamide and Combinations of Ipilimumab, Nivolumab, and Cemiplimab in Treating Relapsed or Refractory Multiple Myeloma, Acute Myeloid Leukemia or Lymphoma

DermatologicLymphoidMyeloidOther hematologic neoplasmPlasma cell

127 enrolled

Immunoblastic Lymphadenopathy, Multiple Myeloma, Mycosis Fungoides, Myelodysplastic Syndromes, Leukemia, Myeloid, Acute, Lymphoma, B-Cell, Lymphoma, T-Cell, Lymphoma, T-Cell, Cutaneous, Lymphoma, Large-Cell, Anaplastic

NCT06508463 2026-04-13

Intravenous Vesicular Stomatitis Virus in Patients With Peripheral T-cell Lymphoma

21 enrolled

Lymphoid

Mycosis Fungoides, Lymphoma, T-Cell, Lymphoma, T-Cell, Peripheral, Lymphoma, Large-Cell, Anaplastic

NCT07134842 2026-04-09

WinGlio-ipi

16 enrolled

CNSSarcoma

Brain Neoplasms, Glioblastoma, Gliosarcoma

NCT02668770 2026-04-07

Ipilimumab (Immunotherapy) and MGN1703 (TLR Agonist) in Patients With Advanced Solid Malignancies

Phase 1 Terminated

28 enrolled

Melanoma, Neoplasm Metastasis, Recurrence

NCT07401875 2026-04-02

A Phase 1b Study of HC-7366, an Agonist of ISR With Immunotherapy in Kidney Cancer (SHARK)

35 enrolled

Kidney Neoplasms

NCT07075120 2026-03-31

Ipilimumab and Nivolumab With SBRT in Locally Advanced Hepatocellular Cancer

15 enrolled

Carcinoma, Hepatocellular

NCT05254184 2026-03-30

KRAS-Targeted Vaccine With Chemoimmunotherapy, Nivolumab and Ipilimumab for Patients With NSCLC

12 enrolled

Carcinoma, Non-Small-Cell Lung

NCT07501117 2026-03-30

Neoadjuvant Immunotherapy for Patients With High-risk Eye Melanoma

15 enrolled

Uveal Melanoma

NCT04943848 2026-03-17

rHSC-DIPGVax Plus Checkpoint Blockade for the Treatment of Newly Diagnosed DIPG and DMG

36 enrolled

Diffuse Intrinsic Pontine Glioma, Glioma

NCT04697576 2026-03-10

Intralesional Influenza Vaccine for the Treatment of Stage I-IV Melanoma

36 enrolled

Melanoma

NCT04013542 2026-03-05

Ipilimumab and Nivolumab in Combination With Radiation Therapy in Treating Patients With Stage 2-3 Non-small Lung Cancer

21 enrolled

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT03223155 2026-03-04

COSINR

78 enrolled

Small Cell Lung Carcinoma

NCT07444619 2026-03-03

A Phase I Study of Pazopanib in Combination With Trabectedin, Ipilimumab and Nivolumab (TraPIN) in Pediatric and Young Adult Patients With Recurrent Soft Tissue Sarcomas

18 enrolled

Sarcoma

NCT04290546 2026-02-27

CIML NK Cell in Head & Neck Cancer

11 enrolled

Head & Neck

Squamous Cell Carcinoma of Head and Neck

NCT07128680 2026-02-27

Immunotherapy (Nivolumab and Ipilimumab) With and Without a Live Biotherapeutic Product (EXL01) for the Treatment of Metastatic Renal Cell Cancer

33 enrolled

Clear-cell metastatic renal cell carcinoma, Carcinoma, Renal Cell

NCT07430202 2026-02-24

A DNAJB1-PRKACA Fusion Kinase Peptide Vaccine Combined With Glutamine Antagonist DRP-104, Nivolumab, and Ipilimumab in Patients With Advanced Stage Fibrolamellar Carcinoma (FLC)

27 enrolled

Fibrolamellar hepatocellular carcinoma, Carcinoma, Liver Neoplasms

NCT03600155 2026-02-17

Nivolumab and Ipilimumab After Donor Stem Cell Transplant in Treating Patients With High Risk Refractory or Relapsed Acute Myeloid Leukemia or Myelodysplastic Syndrome

MyeloidOther hematologic neoplasm

29 enrolled

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute

NCT04606316 2026-02-17

Surgical Nivolumab And Ipilimumab For Recurrent GBM

63 enrolled

Glioblastoma

NCT00586391 2026-02-06

CRETI-NH

LymphoidOther hematologic neoplasm

14 enrolled

Neoplasms, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, B-Cell, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT02950766 2026-02-03

NeoVax Plus Ipilimumab in Renal Cell Carcinoma

19 enrolled

Kidney Neoplasms

NCT04362839 2026-01-28

Regorafenib, Ipilimumab and Nivolumab for the Treatment of Chemotherapy Resistant Microsatellite Stable Metastatic Colorectal Cancer

39 enrolled

Colonic Neoplasms, Rectal Neoplasms, Colorectal Neoplasms

NCT06324240 2026-01-26

Personalized Vaccine Immunotherapy in Combination With Checkpoint Inhibitor for Treatment of Triple Negative Breast Cancer

18 enrolled

Breast

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT06968988 2026-01-08

Zanzalintinib in Combination With Ipilimumab and Nivolumab in Patients With Metastatic Soft Tissue Sarcoma

18 enrolled

Sarcoma

NCT03912064 2026-01-05

A Phase 1 Trial of CD25/Treg-depleted DLI Plus Ipilimumab for Myeloid Disease Relapse After Matched-HCT

MyeloidOther hematologic neoplasm

25 enrolled 17 charts

Myelodysplastic Syndromes, Myeloproliferative Disorders, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic, Primary Myelofibrosis

NCT03929029 2026-01-05

Neoantigen Vaccine Plus Locally Administered Ipilimumab and Systemic Nivolumab in Advanced Melanoma

11 enrolled 11 charts

Melanoma

NCT03245892 2025-12-17

A Study of Carboplatin and Paclitaxel Chemotherapy With Nivolumab With or Without Ipilimumab in Patients With Ovarian Cancer

27 enrolled

Gynecologic

High Grade Serous Ovarian

NCT06889493 2025-12-17

SVV-001 With Nivolumab and Ipilimumab in Patients With Poorly Differentiated Neuroendocrine Carcinomas (NEC) or Well-Differentiated High-Grade Neuroendocrine Tumors (NET)

36 enrolled

EndocrineNET

Carcinoma, Neuroendocrine, Neuroendocrine Tumors

NCT04117087 2025-12-03

Pooled Mutant KRAS-Targeted Long Peptide Vaccine Combined With Nivolumab and Ipilimumab for Patients With Resected Mismatch Repair Protein (MMR-p) Colorectal and Pancreatic Cancer

27 enrolled

Colonic Neoplasms, Pancreatic Neoplasms, Colorectal Neoplasms

NCT04248569 2025-12-03

DNAJB1-PRKACA Fusion Kinase Peptide Vaccine Combined With Nivolumab and Ipilimumab for Patients With Fibrolamellar Hepatocellular Carcinoma

56 enrolled

Fibrolamellar hepatocellular carcinoma

NCT05631899 2025-11-24

CAR-DC Vaccine and ICIs in Local Advanced/Metastatic Solid Tumors

9 enrolled

Tumor-Agnostic

Neoplasm Metastasis

NCT04388852 2025-11-21

DS3201 and Ipilimumab for the Treatment of Metastatic Prostate, Urothelial and Renal Cell Cancers

65 enrolled

Clear-cell metastatic renal cell carcinoma, Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Neoplasm Metastasis, Prostatic Neoplasms

NCT04495257 2025-10-30

A Study of APX005M in Combination With Nivolumab and Ipilimumab in Treatment Naïve Patients With Advanced Melanoma or Renal Cell Carcinoma (RCC)

26 enrolled

Carcinoma, Renal Cell

NCT04465643 2025-10-08

Neoadjuvant Nivolumab Plus Ipilimumab for Newly Diagnosed Malignant Peripheral Nerve Sheath Tumor

13 enrolled

Nerve Sheath Neoplasms

NCT04850755 2025-09-25

A Phase I Dose Escalation Study of Selinexor Plus Nivolumab and Ipilimumab in Advanced/Metastatic Solid Malignancies

11 enrolled

Advance Solid Malignancies

NCT05721846 2025-09-12

CheckVAC

20 enrolled

Pancreatic Neoplasms

NCT05004025 2025-08-15

Single Arm Trial of Tumor-Treating Fields in Combination With Nivolumab and Ipilimumab in Metastatic Uveal Melanoma

10 enrolled

Uveal Melanoma

NCT05262556 2025-08-07

NP-101 (TQ Formula) With Nivolumab and Ipilimumab in Advanced or Metastatic Extra-pulmonary Neuroendocrine Carcinomas

EndocrineGastrointestinalNET

15 enrolled

Gastro-enteropancreatic neuroendocrine tumor, Carcinoma, Neuroendocrine

NCT05341349 2025-07-30

Stereotactic Radiosurgery and Immune Checkpoint Inhibitors With NovoTTF-200M for the Treatment of Melanoma Brain Metastases

1 enrolled

CNSDermatologic

Uveal Melanoma, Brain Neoplasms, Melanoma

NCT03690986 2025-07-23

VX15/2503 in Combination With Ipilimumab or Nivolumab in Patients With Head and Neck Cancer

50 enrolled

Head & Neck

Squamous Cell Carcinoma of Head and Neck

NCT06377111 2025-07-14

A Study to Test the Benefit of Vitamin B5 in Patients With Melanoma

12 enrolled

Melanoma, Skin Neoplasms

NCT04003649 2025-07-10

IL13Ra2-CAR T Cells With or Without Nivolumab and Ipilimumab in Treating Patients With GBM

60 enrolled

BreastDermatologicGenitourinaryGynecologicThoracic

Glioblastoma

NCT02419495 2025-06-04

Phase IB Study to Evaluate the Safety of Selinexor (KPT-330) in Combination With Multiple Standard Chemotherapy or Immunotherapy Agents in Patients With Advanced Malignancies

Phase 1 Terminated

221 enrolled

Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Fallopian Tube Neoplasms, Lung Neoplasms, Melanoma, Neoplasm Metastasis, Ovarian Neoplasms, Triple Negative Breast Neoplasms

NCT03508570 2025-05-22

Nivolumab With or Without Ipilimumab in Treating Patients With Recurrent or High Grade Gynecologic Cancer With Metastatic Peritoneal Carcinomatosis

26 enrolled

Gynecologic

Uterine Cervical Neoplasms, Fallopian Tube Neoplasms, Ovarian Neoplasms, Peritoneal Neoplasms, Endometrial Neoplasms

NCT01703507 2025-05-16

Phase I Study of Ipilimumab Combined With Whole Brain Radiation Therapy or Radiosurgery for Melanoma

17 enrolled 15 charts

CNSDermatologic

Brain Neoplasms, Melanoma

NCT03922880 2025-05-15

Study of Immunotherapy Plus ADI-PEG 20 for the Treatment of Advanced Uveal Melanoma

9 enrolled

Uveal Melanoma

NCT03477864 2025-04-29

Stereotactic Body Radiation Therapy With REGN2810 and/or Ipilimumab Before Surgery in Treating Participants With Progressive Advanced or Oligometastatic Prostate Cancer

Phase 1 Withdrawn

Prostatic Neoplasms

NCT04141644 2025-04-16

Osi+Ipi

24 enrolled

Non-Small Cell Lung Cancer With Mutation in Epidermal Growth Factor Receptor (Disorder)

NCT04239040 2025-03-19

GVAX Plus Checkpoint Blockade in Neuroblastoma

Phase 1 Terminated

19 enrolled